Sponsor content
181 result(s) found, displaying 41 to 50
-
Prescription medicine decision summarySotyktu (deucravacitinib) is approved to treat plaque psoriasis.
-
Prescription medicine registrationActive ingredients: deucravacitinib.
-
Prescription medicine decision summaryCamzyos (mavacamten) is approved to treat cardiomyopathy.
-
Prescription medicine registrationActive ingredients: nivolumab, relatlimab.
-
Prescription medicine registrationActive ingredients: mavacamten.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZEPOSIA ozanimod 920 microgram capsules blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZEPOSIA ozanimod 230 microgram and 460 microgram capsules blister wallet composite pack.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd